Current progress on development of respiratory syncytial virus vaccine

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection, 2) immature immune system and maternal antibodies of newborn infants who are the primary subject population, and 3) imbalanced Th2-biased immune responses to certain vaccine candidates leading to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. A wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vectorbased candidates. Though licensed vaccines remain to be developed, our great efforts will lead us to reach the goal of attaining safe and effective RSV vaccines in the near future.

Original languageEnglish
Pages (from-to)232-237
Number of pages6
JournalBMB Reports
Issue number4
StatePublished - Apr 2011


  • Pathogenesis
  • Protection
  • Respiratory syncytial virus
  • Vaccine
  • Vaccine strategy


Dive into the research topics of 'Current progress on development of respiratory syncytial virus vaccine'. Together they form a unique fingerprint.

Cite this